EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Yerim Jin iD, Yeongju Lee iD

ChemMedChem · 02.12.2024 · 19 (23)

DOI: 10.1002/cmdc.202400267 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 15.10.2024. Verfasst von Yerim Jin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Pusan National University, Busan, 46241, Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Proteolysis, Antineoplastic Agents, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Grant of Pusan National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) accounts for 30 % of cancer cases among women cancer patients globally, indicating the urgent need for the development of selective therapies targeting BCs. Recently, proteolysis‐targeting chimera (PROTAC) has emerged as a promising strategy to target breast cancer. PROTAC is a chimeric molecule consisting of a target protein ligand, an E3 ligase ligand, and conjugating linkers, enabling it to facilitate the degradation of desired target proteins by recruiting E3 ligase in close proximity. Due to the catalytic behavior and direct degradation of BC‐causing proteins, PROTAC could achieve high drug efficacy with low doses, drawing great attention for its potential as therapeutics. This review provides cases of the currently developed PROTACs targeting BCs depending on the type of BCs, limitations, and future perspectives of PROTAC in targeting BCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProteolysisAntineoplastic AgentsUbiquitin-Protein LigasesHumansFemaleLigandsMolecular StructureProteolysis Targeting Chimera

Stichwörter der Autor:innen

Breast cancerERαHER2PROTACTargeted protein degradation

Substanzen

Antineoplastic AgentsUbiquitin-Protein LigasesLigandsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Chemistry, Pusan National University, Busan, 46241, Korea.

ORCID-Profile: Yerim Jin, Yeongju Lee

Förderung

  • Research Grant of Pusan National University

Zitieren

APA

Jin, Y., & Lee, Y. (2024). Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy. ChemMedChem, 19(23). https://doi.org/10.1002/cmdc.202400267

Vancouver

Jin Y, Lee Y. Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy. ChemMedChem. 2024;19(23). doi:10.1002/cmdc.202400267

BibTeX
@article{Jin2024,
  author = {Jin, Yerim and Lee, Yeongju},
  title = {Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy},
  journal = {ChemMedChem},
  year = {2024},
  volume = {19},
  number = {23},
  doi = {10.1002/cmdc.202400267}
}
Kostenlos starten →